Want to see INBP full AI Analyst Report?
Top Page
Integrated BioPharma
(OTC:INBP)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.17
▲(4.38% Upside)
Action:Reiterated
Date:09/29/26
The score is primarily held back by weak financial performance driven by the latest period’s operational disruption (revenue at zero) and large net loss, despite positive cash flow and manageable leverage. Technicals are neutral with limited momentum and a weak longer-term trend versus the 200-day average, while valuation is constrained by losses (negative P/E). Corporate events provide a small positive offset via operational leadership changes and extended credit access.
Positive Factors
Manageable Leverage
A relatively stable capital structure gives INBP financial flexibility while it addresses operating challenges. Manageable leverage can support continued investment and reduce balance-sheet pressure, although the 2026 increase in debt and lower equity warrants monitoring.
Negative Factors
Revenue and Earnings Collapse
Revenue falling to zero alongside a sizeable net loss represents a severe breakdown in current operating performance. It weakens earnings visibility, limits internally funded growth and raises uncertainty about the company’s ability to restore consistent commercial activity.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable Leverage
A relatively stable capital structure gives INBP financial flexibility while it addresses operating challenges. Manageable leverage can support continued investment and reduce balance-sheet pressure, although the 2026 increase in debt and lower equity warrants monitoring.
Read all positive factors
Integrated BioPharma (INBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.65M
Dividend YieldN/A
Average Volume (3M)11.03K
Price to Earnings (P/E)―
Beta (1Y)0.01
Revenue Growth-19.28%
EPS Growth-441.42%
CountryUS
Employees134
SectorConsumer Defensive
Sector Strength42
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.09
Shares Outstanding31,059,610
10 Day Avg. Volume23,772
30 Day Avg. Volume11,027
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.32
Price to Sales (P/S)0.13
P/FCF Ratio6.25
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Integrated BioPharma Business Overview & Revenue Model
Company Description
Integrated BioPharma, Inc., together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operate...
How the Company Makes Money
INBP primarily makes money by providing contract manufacturing and related services to third-party nutraceutical and dietary supplement brands. Key revenue streams typically include (1) manufacturing fees for producing finished supplement products...
Integrated BioPharma Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
63
Positive
Cash Flow
46
Neutral
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 43.87M | 54.35M | 50.32M | 50.67M | 56.25M |
| Gross Profit | 800.00K | 5.56M | 3.88M | 4.06M | 6.55M |
| EBITDA | -1.32M | 3.38M | 1.47M | 1.27M | 3.56M |
| Net Income | -2.84M | 808.00K | 112.00K | -34.00K | 3.84M |
Balance Sheet | |||||
| Total Assets | 25.34M | 24.90M | 26.21M | 25.43M | 25.25M |
| Cash, Cash Equivalents and Short-Term Investments | 4.47M | 3.62M | 1.68M | 1.32M | 331.00K |
| Total Debt | 3.08M | 1.01M | 1.80M | 2.67M | 2.06M |
| Total Liabilities | 7.67M | 4.58M | 6.97M | 6.57M | 6.67M |
| Stockholders Equity | 17.67M | 20.32M | 19.24M | 18.86M | 18.57M |
Cash Flow | |||||
| Free Cash Flow | 895.00K | 1.87M | 390.00K | 1.12M | 3.60M |
| Operating Cash Flow | 1.24M | 2.06M | 943.00K | 1.23M | 4.09M |
| Investing Cash Flow | -340.00K | -205.00K | -553.00K | -111.00K | -465.00K |
| Financing Cash Flow | -45.00K | 78.00K | -29.00K | -136.00K | -3.50M |
Integrated BioPharma Technical Analysis
Positive
0.16
Price Trends
0.17
Positive
0.18
Positive
0.24
Negative
Market Momentum
<0.01
Positive
53.03
Neutral
44.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBP, the sentiment is Positive. The current price of 0.16 is below the 20-day moving average (MA) of 0.18, below the 50-day MA of 0.17, and below the 200-day MA of 0.24, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 53.03 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INBP.
Integrated BioPharma Risk Analysis
Integrated BioPharma disclosed 20 risk factors in its most recent earnings report. Integrated BioPharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Integrated BioPharma Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $87.15M | 13.97 | 13.98% | ― | 60.61% | -22.94% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
46 Neutral | $5.65M | -1.97 | -14.78% | ― | -19.28% | -441.42% | |
45 Neutral | $9.61M | -0.50 | -20.98% | ― | -12.92% | -173.30% | |
43 Neutral | $45.53M | -0.05 | -1651.95% | ― | ― | ― | |
41 Neutral | $9.26M | -0.43 | -33.23% | ― | 9.08% | -52.59% |
* Consumer Defensive Sector Average
INBP
Integrated BioPharma
0.18
-0.11
-39.31%
NAII
Natural Alternatives International
1.48
-1.28
-46.38%
SOWG
Sow Good
2.28
-10.92
-82.73%
FTLF
FitLife Brands
9.22
-10.52
-53.29%
BON
Bon Natural Life
1.14
-0.91
-44.39%
Integrated BioPharma Corporate Events
Business Operations and StrategyExecutive/Board Changes
Integrated BioPharma Subsidiary Appoints New Head of Operations
Positive
Aug 20, 2026
On August 20, 2026, Integrated BioPharma’s wholly owned subsidiary Manhattan Drug Company announced that industry veteran Michael G. Richtmyer joined the company on August 3, 2026 as Head of Operations. Richtmyer brings more than 35 years of...
Business Operations and StrategyPrivate Placements and Financing
Integrated BioPharma Updates and Extends Credit Facilities
Positive
Jul 2, 2026
On June 30, 2026, Integrated BioPharma and Manhattan Drug Company amended their loan arrangements with PNC Bank, extending the expiration of their existing committed revolving line of credit to April 14, 2027 while maintaining the $4,000,000 borro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.